UCB SA - BNP Paribas Fortis

More documents

Recommendations

Info

PART X: ASSOCIATED COMPANIES AND SHAREHOLDINGS UCB is currently the parent company, directly or indirectly, of the following Belgian and foreign companies. Company name Registered office Celltech Group Ltd. .............................................. 208 Bath Road, Slough, Berkshire, S14 3WE U.K. Celltech Insurance Ltd. ........................................ 4th fl St. James House 25-29 Adelaide Road, Dublin 2, Ireland Celltech Japan Ltd. ............................................... 208 Bath Road, Slough, Berkshire, S14 3WE U.K. Celltech Ltd. ......................................................... 208 Bath Road, Slough, Berkshire, S14 3WE U.K. Celltech Manufacturing CA, Inc. ......................... 3130 South Harbor Blvd, 92704 Sta Anna California, U.S.A. A11250830/2.25/23 Oct 2009 108 Percentage Voting rights at shareholders’ meeting Celltech Pharma Beteiligungs GmbH .................. Bamlerstrasse 1B, 45141 Essen, Germany 100 Celltech Pharma Europe Ltd. ............................... 208 Bath Road, Slough, Berkshire, S14 3WE U.K. Celltech Pharma GmbH & Co Kg ........................ Bamlerstrasse 1B, 45141 Essen, Germany 100 Celltech Pharma Ireland ....................................... United Drug House Belgard Road, Tallaght, Dublin 24, Ireland Celltech Reinsurance Ltd. .................................... 4th fl St. James House 25-29 Adelaide Road, Dublin 2, Ireland Celltech Research & Development Ltd. ............... 208 Bath Road, Slough, Berkshire, S14 3WE U.K. Celltech US LLC .................................................. The Corporation Trust Company Corporation Trust Center 1209 Orange Street, Wilmington, Delaware 19801, U.S.A. Chiroscience Group Ltd. ...................................... 208 Bath Road, Slough, Berkshire, S14 3WE U.K. Chiroscience Research & Development Ltd . ....... 208 Bath Road, Slough, Berkshire, S14 3WE U.K. 100 100 100 100 100 100 100 100 100 100 100 100
Company name Registered office Cistron Biotechnology Inc. .................................. 10 Bloomfield Ave Pine Brook, 07058 New Jersey, U.S.A. Cogefina S.A. ....................................................... ZI de Planchy Chemin de Croix Blanche 10, 1630 Bulle, Switzerland Confirmant Ltd. .................................................... 208 Bath Road, Slough, Berkshire, S14 3WE U.K. CPM Properties Inc .............................................. The Corporation Trust Company Corporation Trust Center 1209 Orange Street, Wilmington, Delaware 19801, U.S.A. Darwin Discovery Ltd. ......................................... 208 Bath Road, Slough, Berkshire, S14 3WE U.K. Doutors Réassurance S.A. .................................... ZI de Planchy Chemin de Croix Blanche 10, 1630 Bulle, Switzerland Evans Healthcare .................................................. 208 Bath Road, Slough, Berkshire, S14 3WE U.K. Fin. UCB S.A. ...................................................... Allée de la Recherche 60, 1070 Brussels, Belgium Fipar ..................................................................... 208 Bath Road, Slough, Berkshire, S14 3WE U.K. Fipar UK Ltd. ....................................................... 208 Bath Road, Slough, Berkshire, S14 3WE U.K. Fipar US Inc. ........................................................ The Corporation Trust Company Corporation Trust Center 1209 Orange Street, Wilmington, Delaware 19801, U.S.A. Ilika Epikalipseon Helias EPE (in liquidation) .... 39-42 Grigoriou Lambraki and Ulof Palme, Str 2, 14123 Likovrissi Attika, Greece International Medication Systems (UK) Ltd. ....... 208 Bath Road, Slough, Berkshire, S14 3WE U.K. Korea UCB Co., Ltd ............................................. 5F Buwoon B/D 807/2 Bangbaedong Seochogu, 13760 Seoul, Korea Kremers Urban Development Company .............. The Corporation Trust Company Corporation Trust Center 1209 Orange Street, Wilmington, Delaware 19801, U.S.A. A11250830/2.25/23 Oct 2009 109 Percentage Voting rights at shareholders’ meeting 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
Page 1 and 2:
A11250830/2.25/23 Oct 2009 UCB SA (
Page 3 and 4:
A11250830/2.25/23 Oct 2009 3 RESPON
Page 5 and 6:
A11250830/2.25/23 Oct 2009 5 WARNIN
Page 7 and 8:
A11250830/2.25/23 Oct 2009 7 PART I
Page 9 and 10:
Specified Denomination per Bond Min
Page 11 and 12:
Trading on the regulated market of
Page 13 and 14:
- Reliance on the procedures of the
Page 15 and 16:
and federal governmental entities,
Page 17 and 18:
If any of the UCB Group’s major p
Page 19 and 20:
The UCB Group relies upon third-par
Page 21 and 22:
other U.S. federal and state govern
Page 23 and 24:
either to remediate certain sites o
Page 25 and 26:
(iii) have sufficient financial res
Page 27 and 28:
(i) EU Savings Directive Under the
Page 29 and 30:
(o) The Domiciliary Agent is not re
Page 31 and 32:
PART III: DOCUMENTS INCORPORATED BY
Page 33 and 34:
• Press release of 26 June 2009:
Page 35 and 36:
The Bonds constitute direct, uncond
Page 37 and 38:
“Interest Payment Date” has the
Page 39 and 40:
When interest is required to be cal
Page 41 and 42:
"Calculation Agent" means Fortis Ba
Page 43 and 44:
The Issuer reserves the right under
Page 45 and 46:
any step is taken to enforce it (in
Page 47 and 48:
12 Notices Notices to the Bondholde
Page 49 and 50:
1. SUMMARY PART VI: DESCRIPTION OF
Page 51 and 52:
Marketing & selling expenses Resear
Page 53 and 54:
In 2008, the Issuer announced sever
Page 55 and 56:
Issuer is developing from its stron
Page 57 and 58: Parkinson’s disease. Following a
Page 59 and 60: Keppra® is one of the core product
Page 61 and 62: that remission is possible with no
Page 63 and 64: (d) Manufacturing and supply of raw
Page 65 and 66: NET SALES FOR MAIN PRODUCTS BY REGI
Page 67 and 68: (a) a strategic focus on severe CNS
Page 69 and 70: ongoing and results are expected du
Page 71 and 72: Cimzia® (certolizumab pegol) Cimzi
Page 73 and 74: • Pfizer Inc.: The UCB Group is p
Page 75 and 76: esearch, regulatory, manufacturing,
Page 77 and 78: Neupro® (rotigotine; patch) Februa
Page 79 and 80: Before a drug can qualify for marke
Page 81 and 82: control mechanisms operate differen
Page 83 and 84: year term following a specific regu
Page 85 and 86: pain; which expires with the last t
Page 87 and 88: Group. The UCB Group treats any cla
Page 89 and 90: (g) Distilbène Litigation As of th
Page 91 and 92: (n) Competition enquiry in France T
Page 93 and 94: 3 These Directors are representativ
Page 95 and 96: Norman J-Ornstein was appointed to
Page 97 and 98: Mark McDade joined the Issuer as ex
Page 99 and 100: esults or information which is liab
Page 101 and 102: Peter Fellner......................
Page 103 and 104: • the closing price of the Ordina
Page 105 and 106: A11250830/2.25/23 Oct 2009 105 PART
Page 107: A11250830/2.25/23 Oct 2009 107 PART
Page 111 and 112: Company name Registered office Schw
Page 113 and 114: Company name Registered office UCB
Page 115 and 116: Company name Registered office UCB
Page 117 and 118: PART XI: DESCRIPTION OF THE SHARES
Page 119 and 120: According to article 32 of the Arti
Page 121 and 122: Under UCB’s Articles, the Issuer
Page 123 and 124: The Board can also determine when s
Page 125 and 126: 1. BELGIAN TAXATION PART XIII: TAXA
Page 127 and 128: (b) Belgian tax on income and capit
Page 129 and 130: more detailed proposal for amendmen
Page 131 and 132: PART XIV: SUBSCRIPTION AND SALE For
Page 133 and 134: On the date that the subscriptions
Page 135 and 136: 12. DISTRIBUTION OF THE PROSPECTUS
Page 137 and 138: PART XV: GENERAL INFORMATION 1. App
Page 139 and 140: A11250830/2.25/23 Oct 2009 139 Subs
Page 141 and 142: Addressee UCB SA (the « Issuer »)
show all

UCB SA - BNP Paribas Fortis

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?